Standardized uptake value on FDG-PET as a marker for disease activity in patients with non-Hodgkin’s lymphoma: comparison with serum soluble interleukin-2 receptor values
Background We compared standardized uptake values (SUVs) on positron emission tomography with a glucose analog, 2-[F-18] fluoro-2-deoxy-D-glucose (FDG-PET) and serum soluble interleukin-2 receptor (sIL-2R) values in patients with non-Hodgkin’s lymphoma (NHL) in the pre-, mid- (after three or four cy...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical oncology 2009-04, Vol.14 (2), p.150-158 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 158 |
|---|---|
| container_issue | 2 |
| container_start_page | 150 |
| container_title | International journal of clinical oncology |
| container_volume | 14 |
| creator | Tatsumi, Mitsuaki Sugahara, Hiroyuki Higuchi, Ichiro Fukunaga, Hiroki Nakamura, Hironobu Kanakura, Yuzuru Hatazawa, Jun |
| description | Background
We compared standardized uptake values (SUVs) on positron emission tomography with a glucose analog, 2-[F-18] fluoro-2-deoxy-D-glucose (FDG-PET) and serum soluble interleukin-2 receptor (sIL-2R) values in patients with non-Hodgkin’s lymphoma (NHL) in the pre-, mid- (after three or four cycles), and post-treatment periods of chemotherapy (pre, mid, and post, respectively), and we examined whether the SUV was a useful tumor marker for NHL.
Methods
The SUVs on PET and sIL-2R values were retrospectively evaluated based on all the clinical information available in 40 patients (31 in pre, 24 in mid, and 24 in the post periods). Patients in complete remission status were classified as group A and those with active residual disease in the mid and post periods were classified as group B.
Results
In pre, the SUV and sIL-2R values exhibited sensitivity of 100% and 84%, respectively. In mid, the SUV was lower in group A than in group B, while sIL-2R was not different. The SUV yielded better specificity than sIL-2R (88 % vs 25 %, respectively), though the difference was not significant. In mid, the SUV in patients later assigned to group A in post was lower than than the SUV in group B, whereas sIL-2R was not different. In post, the specificity and accuracy of SUV were better than those of sIL-2R (95 vs 47 %, and 96 vs 58 %, respectively). Both the SUV and sIL-2R were lower in group A than in group B.
Conclusion
The SUV on PET was better than the serum sIL-2R as a marker to evaluate the disease status of NHL, and was considered to be a useful tumor marker for NHL. |
| doi_str_mv | 10.1007/s10147-008-0823-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67160876</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67160876</sourcerecordid><originalsourceid>FETCH-LOGICAL-c429t-cfb1458083268345a201f7b678fc383f6fd277ffc62c4832bd6fe8cd7d7dfad03</originalsourceid><addsrcrecordid>eNqFkc1qFTEcxYMotl59ADcSXLiL5mMmmXEntR9CQcG6Dpl8tOmdScYkU3td-Rq-g0_lk5jbe6EgiGSRQH7nnH9yAHhO8GuCsXiTCSaNQBh3CHeUodsH4JA0TCAhBH1Yz6whqOe0PQBPcr7GmAje0sfggPSsx30jDsGvz0UFo5Lx362By1zU2sIbNS4WxgBP3p-iT8cXUGWo4KTS2iboYoLGZ6uyhUoXf-PLBvoAZ1W8DSXDb75cwRADOovmcu3D7x8_Mxw303wVJ_UW6jjNKvlc7e_IbNMywRzHZRhtNSo2jXapOkRhstrOpQbeTZSfgkdOjdk-2-8r8OXk-OLoDJ1_PP1w9O4c6Yb2BWk3kKbtcMco71jTKoqJEwMXndOsY447Q4VwTnOqmwoNhjvbaSPqcspgtgKvdr5zil9rbpGTz9qOowo2LllyQTjuBP8vSAkRoq9DrMDLv8DruKRQHyEpZj1rWb91IztIp5hzsk7Oyddf30iC5bZwuStc1sLltnB5WzUv9sbLMFlzr9g3XAG6A3K9Cpc23Sf_2_UPfyu6sA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>203935396</pqid></control><display><type>article</type><title>Standardized uptake value on FDG-PET as a marker for disease activity in patients with non-Hodgkin’s lymphoma: comparison with serum soluble interleukin-2 receptor values</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Tatsumi, Mitsuaki ; Sugahara, Hiroyuki ; Higuchi, Ichiro ; Fukunaga, Hiroki ; Nakamura, Hironobu ; Kanakura, Yuzuru ; Hatazawa, Jun</creator><creatorcontrib>Tatsumi, Mitsuaki ; Sugahara, Hiroyuki ; Higuchi, Ichiro ; Fukunaga, Hiroki ; Nakamura, Hironobu ; Kanakura, Yuzuru ; Hatazawa, Jun</creatorcontrib><description>Background
We compared standardized uptake values (SUVs) on positron emission tomography with a glucose analog, 2-[F-18] fluoro-2-deoxy-D-glucose (FDG-PET) and serum soluble interleukin-2 receptor (sIL-2R) values in patients with non-Hodgkin’s lymphoma (NHL) in the pre-, mid- (after three or four cycles), and post-treatment periods of chemotherapy (pre, mid, and post, respectively), and we examined whether the SUV was a useful tumor marker for NHL.
Methods
The SUVs on PET and sIL-2R values were retrospectively evaluated based on all the clinical information available in 40 patients (31 in pre, 24 in mid, and 24 in the post periods). Patients in complete remission status were classified as group A and those with active residual disease in the mid and post periods were classified as group B.
Results
In pre, the SUV and sIL-2R values exhibited sensitivity of 100% and 84%, respectively. In mid, the SUV was lower in group A than in group B, while sIL-2R was not different. The SUV yielded better specificity than sIL-2R (88 % vs 25 %, respectively), though the difference was not significant. In mid, the SUV in patients later assigned to group A in post was lower than than the SUV in group B, whereas sIL-2R was not different. In post, the specificity and accuracy of SUV were better than those of sIL-2R (95 vs 47 %, and 96 vs 58 %, respectively). Both the SUV and sIL-2R were lower in group A than in group B.
Conclusion
The SUV on PET was better than the serum sIL-2R as a marker to evaluate the disease status of NHL, and was considered to be a useful tumor marker for NHL.</description><identifier>ISSN: 1341-9625</identifier><identifier>EISSN: 1437-7772</identifier><identifier>DOI: 10.1007/s10147-008-0823-x</identifier><identifier>PMID: 19390947</identifier><language>eng</language><publisher>Japan: Springer Japan</publisher><subject>Aged ; Cancer Research ; Female ; Fluorodeoxyglucose F18 ; Humans ; Lymphoma ; Lymphoma, Non-Hodgkin - blood ; Lymphoma, Non-Hodgkin - diagnostic imaging ; Lymphoma, Non-Hodgkin - drug therapy ; Male ; Medical diagnosis ; Medicine ; Medicine & Public Health ; Middle Aged ; Nuclear medicine ; Oncology ; Original Article ; Positron-Emission Tomography ; Radiopharmaceuticals ; Receptors, Interleukin-2 - blood ; Surgical Oncology ; Tomography</subject><ispartof>International journal of clinical oncology, 2009-04, Vol.14 (2), p.150-158</ispartof><rights>Japan Society of Clinical Oncology 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c429t-cfb1458083268345a201f7b678fc383f6fd277ffc62c4832bd6fe8cd7d7dfad03</citedby><cites>FETCH-LOGICAL-c429t-cfb1458083268345a201f7b678fc383f6fd277ffc62c4832bd6fe8cd7d7dfad03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10147-008-0823-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10147-008-0823-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19390947$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tatsumi, Mitsuaki</creatorcontrib><creatorcontrib>Sugahara, Hiroyuki</creatorcontrib><creatorcontrib>Higuchi, Ichiro</creatorcontrib><creatorcontrib>Fukunaga, Hiroki</creatorcontrib><creatorcontrib>Nakamura, Hironobu</creatorcontrib><creatorcontrib>Kanakura, Yuzuru</creatorcontrib><creatorcontrib>Hatazawa, Jun</creatorcontrib><title>Standardized uptake value on FDG-PET as a marker for disease activity in patients with non-Hodgkin’s lymphoma: comparison with serum soluble interleukin-2 receptor values</title><title>International journal of clinical oncology</title><addtitle>Int J Clin Oncol</addtitle><addtitle>Int J Clin Oncol</addtitle><description>Background
We compared standardized uptake values (SUVs) on positron emission tomography with a glucose analog, 2-[F-18] fluoro-2-deoxy-D-glucose (FDG-PET) and serum soluble interleukin-2 receptor (sIL-2R) values in patients with non-Hodgkin’s lymphoma (NHL) in the pre-, mid- (after three or four cycles), and post-treatment periods of chemotherapy (pre, mid, and post, respectively), and we examined whether the SUV was a useful tumor marker for NHL.
Methods
The SUVs on PET and sIL-2R values were retrospectively evaluated based on all the clinical information available in 40 patients (31 in pre, 24 in mid, and 24 in the post periods). Patients in complete remission status were classified as group A and those with active residual disease in the mid and post periods were classified as group B.
Results
In pre, the SUV and sIL-2R values exhibited sensitivity of 100% and 84%, respectively. In mid, the SUV was lower in group A than in group B, while sIL-2R was not different. The SUV yielded better specificity than sIL-2R (88 % vs 25 %, respectively), though the difference was not significant. In mid, the SUV in patients later assigned to group A in post was lower than than the SUV in group B, whereas sIL-2R was not different. In post, the specificity and accuracy of SUV were better than those of sIL-2R (95 vs 47 %, and 96 vs 58 %, respectively). Both the SUV and sIL-2R were lower in group A than in group B.
Conclusion
The SUV on PET was better than the serum sIL-2R as a marker to evaluate the disease status of NHL, and was considered to be a useful tumor marker for NHL.</description><subject>Aged</subject><subject>Cancer Research</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18</subject><subject>Humans</subject><subject>Lymphoma</subject><subject>Lymphoma, Non-Hodgkin - blood</subject><subject>Lymphoma, Non-Hodgkin - diagnostic imaging</subject><subject>Lymphoma, Non-Hodgkin - drug therapy</subject><subject>Male</subject><subject>Medical diagnosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Nuclear medicine</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Positron-Emission Tomography</subject><subject>Radiopharmaceuticals</subject><subject>Receptors, Interleukin-2 - blood</subject><subject>Surgical Oncology</subject><subject>Tomography</subject><issn>1341-9625</issn><issn>1437-7772</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkc1qFTEcxYMotl59ADcSXLiL5mMmmXEntR9CQcG6Dpl8tOmdScYkU3td-Rq-g0_lk5jbe6EgiGSRQH7nnH9yAHhO8GuCsXiTCSaNQBh3CHeUodsH4JA0TCAhBH1Yz6whqOe0PQBPcr7GmAje0sfggPSsx30jDsGvz0UFo5Lx362By1zU2sIbNS4WxgBP3p-iT8cXUGWo4KTS2iboYoLGZ6uyhUoXf-PLBvoAZ1W8DSXDb75cwRADOovmcu3D7x8_Mxw303wVJ_UW6jjNKvlc7e_IbNMywRzHZRhtNSo2jXapOkRhstrOpQbeTZSfgkdOjdk-2-8r8OXk-OLoDJ1_PP1w9O4c6Yb2BWk3kKbtcMco71jTKoqJEwMXndOsY447Q4VwTnOqmwoNhjvbaSPqcspgtgKvdr5zil9rbpGTz9qOowo2LllyQTjuBP8vSAkRoq9DrMDLv8DruKRQHyEpZj1rWb91IztIp5hzsk7Oyddf30iC5bZwuStc1sLltnB5WzUv9sbLMFlzr9g3XAG6A3K9Cpc23Sf_2_UPfyu6sA</recordid><startdate>20090401</startdate><enddate>20090401</enddate><creator>Tatsumi, Mitsuaki</creator><creator>Sugahara, Hiroyuki</creator><creator>Higuchi, Ichiro</creator><creator>Fukunaga, Hiroki</creator><creator>Nakamura, Hironobu</creator><creator>Kanakura, Yuzuru</creator><creator>Hatazawa, Jun</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7T5</scope><scope>7X8</scope></search><sort><creationdate>20090401</creationdate><title>Standardized uptake value on FDG-PET as a marker for disease activity in patients with non-Hodgkin’s lymphoma: comparison with serum soluble interleukin-2 receptor values</title><author>Tatsumi, Mitsuaki ; Sugahara, Hiroyuki ; Higuchi, Ichiro ; Fukunaga, Hiroki ; Nakamura, Hironobu ; Kanakura, Yuzuru ; Hatazawa, Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c429t-cfb1458083268345a201f7b678fc383f6fd277ffc62c4832bd6fe8cd7d7dfad03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Aged</topic><topic>Cancer Research</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18</topic><topic>Humans</topic><topic>Lymphoma</topic><topic>Lymphoma, Non-Hodgkin - blood</topic><topic>Lymphoma, Non-Hodgkin - diagnostic imaging</topic><topic>Lymphoma, Non-Hodgkin - drug therapy</topic><topic>Male</topic><topic>Medical diagnosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Nuclear medicine</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Positron-Emission Tomography</topic><topic>Radiopharmaceuticals</topic><topic>Receptors, Interleukin-2 - blood</topic><topic>Surgical Oncology</topic><topic>Tomography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tatsumi, Mitsuaki</creatorcontrib><creatorcontrib>Sugahara, Hiroyuki</creatorcontrib><creatorcontrib>Higuchi, Ichiro</creatorcontrib><creatorcontrib>Fukunaga, Hiroki</creatorcontrib><creatorcontrib>Nakamura, Hironobu</creatorcontrib><creatorcontrib>Kanakura, Yuzuru</creatorcontrib><creatorcontrib>Hatazawa, Jun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Immunology Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tatsumi, Mitsuaki</au><au>Sugahara, Hiroyuki</au><au>Higuchi, Ichiro</au><au>Fukunaga, Hiroki</au><au>Nakamura, Hironobu</au><au>Kanakura, Yuzuru</au><au>Hatazawa, Jun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Standardized uptake value on FDG-PET as a marker for disease activity in patients with non-Hodgkin’s lymphoma: comparison with serum soluble interleukin-2 receptor values</atitle><jtitle>International journal of clinical oncology</jtitle><stitle>Int J Clin Oncol</stitle><addtitle>Int J Clin Oncol</addtitle><date>2009-04-01</date><risdate>2009</risdate><volume>14</volume><issue>2</issue><spage>150</spage><epage>158</epage><pages>150-158</pages><issn>1341-9625</issn><eissn>1437-7772</eissn><abstract>Background
We compared standardized uptake values (SUVs) on positron emission tomography with a glucose analog, 2-[F-18] fluoro-2-deoxy-D-glucose (FDG-PET) and serum soluble interleukin-2 receptor (sIL-2R) values in patients with non-Hodgkin’s lymphoma (NHL) in the pre-, mid- (after three or four cycles), and post-treatment periods of chemotherapy (pre, mid, and post, respectively), and we examined whether the SUV was a useful tumor marker for NHL.
Methods
The SUVs on PET and sIL-2R values were retrospectively evaluated based on all the clinical information available in 40 patients (31 in pre, 24 in mid, and 24 in the post periods). Patients in complete remission status were classified as group A and those with active residual disease in the mid and post periods were classified as group B.
Results
In pre, the SUV and sIL-2R values exhibited sensitivity of 100% and 84%, respectively. In mid, the SUV was lower in group A than in group B, while sIL-2R was not different. The SUV yielded better specificity than sIL-2R (88 % vs 25 %, respectively), though the difference was not significant. In mid, the SUV in patients later assigned to group A in post was lower than than the SUV in group B, whereas sIL-2R was not different. In post, the specificity and accuracy of SUV were better than those of sIL-2R (95 vs 47 %, and 96 vs 58 %, respectively). Both the SUV and sIL-2R were lower in group A than in group B.
Conclusion
The SUV on PET was better than the serum sIL-2R as a marker to evaluate the disease status of NHL, and was considered to be a useful tumor marker for NHL.</abstract><cop>Japan</cop><pub>Springer Japan</pub><pmid>19390947</pmid><doi>10.1007/s10147-008-0823-x</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1341-9625 |
| ispartof | International journal of clinical oncology, 2009-04, Vol.14 (2), p.150-158 |
| issn | 1341-9625 1437-7772 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67160876 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Aged Cancer Research Female Fluorodeoxyglucose F18 Humans Lymphoma Lymphoma, Non-Hodgkin - blood Lymphoma, Non-Hodgkin - diagnostic imaging Lymphoma, Non-Hodgkin - drug therapy Male Medical diagnosis Medicine Medicine & Public Health Middle Aged Nuclear medicine Oncology Original Article Positron-Emission Tomography Radiopharmaceuticals Receptors, Interleukin-2 - blood Surgical Oncology Tomography |
| title | Standardized uptake value on FDG-PET as a marker for disease activity in patients with non-Hodgkin’s lymphoma: comparison with serum soluble interleukin-2 receptor values |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T04%3A23%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Standardized%20uptake%20value%20on%20FDG-PET%20as%20a%20marker%20for%20disease%20activity%20in%20patients%20with%20non-Hodgkin%E2%80%99s%20lymphoma:%20comparison%20with%20serum%20soluble%20interleukin-2%20receptor%20values&rft.jtitle=International%20journal%20of%20clinical%20oncology&rft.au=Tatsumi,%20Mitsuaki&rft.date=2009-04-01&rft.volume=14&rft.issue=2&rft.spage=150&rft.epage=158&rft.pages=150-158&rft.issn=1341-9625&rft.eissn=1437-7772&rft_id=info:doi/10.1007/s10147-008-0823-x&rft_dat=%3Cproquest_cross%3E67160876%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=203935396&rft_id=info:pmid/19390947&rfr_iscdi=true |